BEVERLY, Mass. and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three months ended March 31, 2024 before market open on Tuesday, May 14, 2024. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedar.com.
The Company will follow with a conference call on the same day at 9:00 a.m. EDT to review highlights of the results.
All interested parties are welcome to join the conference call by dialing toll free 1-833-366-1126 in North America, or 1-412-317-0703 from other locations, and requesting the “Hamilton Thorne Conference Call.” The Company’s updated investor presentation and a recording of the call will be available on Hamilton Thorne’s website shortly after the call.
About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)
Hamilton Thorne is a leading global provider of precision instruments, laboratory equipment, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, Gynetics, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne Ltd.’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the TSX, nor its regulation services provider (as that term is defined in the policies of the TSX), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
| Kate Torchilin, Pres. & CEO | Francesco Fragasso, CFO | Glen Akselrod |
| Hamilton Thorne Ltd. | Hamilton Thorne Ltd. | Bristol Investor Relations |
| 978-921-2050 | 978-921-2050 | 905-326-1888 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | C$2.24 |
| Daily Volume: | 0 |
| Market Cap: | C$345.340M |
November 14, 2024 August 14, 2024 July 22, 2024 May 14, 2024 April 10, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
